Advertisement

Journal of Gastrointestinal Surgery

, Volume 14, Issue 4, pp 607–613 | Cite as

Outcome After Curative Resection of Large (≥10 cm) Gastric Gastrointestinal Stromal Tumors: How Frequent is Adjacent Organ Involvement and is Concomitant Distal Pancreatectomy Necessary?

  • Brian K. P. Goh
  • Pierce K. H. Chow
  • Sittampalam M. Kesavan
  • Wai-Ming Yap
  • Yaw-Fui A. Chung
  • Wai-Keong Wong
Original Article

Abstract

Introduction

Complete tumor resection with clear margins including adjacent organs is the treatment of choice for gastrointestinal stromal tumors (GISTs). However, true tumor invasion of adjacent organs has been reported to be rare. Concomitant distal pancreatectomy (DP) for suspected tumor infiltration is not infrequently performed during resection of large gastric GISTs. This study aims to determine the true frequency of adjacent organ involvement by large gastric GISTs with particular attention to the pancreas and compares the outcome after curative resection with and without a concomitant DP in order to determine if DP is truly necessary.

Methods

A retrospective review of 37 patients who underwent curative resection of large (≥10 cm) gastric GISTs was conducted.

Results

Wedge resections were performed in 22, partial gastectomies in nine, and total gastrectomies in six patients. The median operative time was 180 min (range, 60–330 min), and the patients had a median postoperative stay of 8 days (range, 4–29 days). Overall, there were eight (22%) morbidities including two (5%) mortalities. Nineteen (51%) had concomitant adjacent organ resection, and these included 15 (41%) DPs with splenectomies. Direct organ invasion was demonstrated in 5/19 patients (26%) and 7/30 organs (23%) resected. Only 1/15 (6.7%) DP specimens demonstrated tumor infiltration. Comparison between the patients with and without a concomitant DP demonstrated that performance of a DP was associated with a longer operation time [225 min (range, 105–305 min) vs 158 min (60–330 min), P = .002)], increased postoperative stay [9 days (range, 7–29 days) vs 7.5 days (4–19 days), P = .042], and increased postoperative morbidity [6 (40%) vs 2 (9%), P = .025]. The DP cohort also had a statistically significant poorer 5-year recurrence free survival (22% vs 60%, P = .017).

Conclusion

Although adjacent organ involvement is not uncommon with large gastric GISTs, concomitant DP is usually unnecessary as direct pancreatic invasion is rare. Furthermore, concomitant DP with splenectomy is associated with an increase in postoperative morbidity.

Keywords

Gastrointestinal stromal tumor GIST Gastric Pancreatectomy Surgery Large 

References

  1. 1.
    Connolly EM, Gaffney E, Reynolds JV. Gastrointestinal stromal tumors. Br J Surg 2003;90:1178–1186.CrossRefPubMedGoogle Scholar
  2. 2.
    Winfield RD, Hochwald SN, Vogel SB, Hemming AW, Liu C, Cance WG, Grobmyer SR. Presentation and management of gastrointestinal stromal tumors of the duodenum. Am Surg 2006;72:719–723.PubMedGoogle Scholar
  3. 3.
    Goh BK, Chow PK, Ong HS, Wong WK. Gastrointestinal stromal tumor involving the second and third portion of the duodenum: treatment by partial duodenectomy and Roux-en-Y duodenojejunostomy. J Surg Oncol 2005;91:273–275.CrossRefPubMedGoogle Scholar
  4. 4.
    Pidhorecky I, Cheney RT, Kraybill WG, Gibbs JF. Gastrointestinal stromal tumors: Current diagnosis, biologic behavior, and management. Ann Surg Oncol 2000;7:705–712.CrossRefPubMedGoogle Scholar
  5. 5.
    Dematteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors. Recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51–58.CrossRefPubMedGoogle Scholar
  6. 6.
    Goh BK, Chow PK, Yap WM, Kesavan SM, Song IC, Paul PG, Ooi BS, Chung YF, Wong WK. Which is the optimal risk stratification system for surgically treated localize primary GIST? Comparison of three contemporary prognostic criteria in 171 tumors and a proposal of a modified Armed Forces Institute of Pathology risk criteria. Ann Surg Oncol 2008;15:2153–2163.CrossRefPubMedGoogle Scholar
  7. 7.
    Shiu MH, Farr GH, Papachristou DN, Hajdu SI. Myosarcomas of the stomach: natural history, prognostic factors and management. Cancer 1982;49:177–187.CrossRefPubMedGoogle Scholar
  8. 8.
    Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach. A clinicopathologic, immunohistochemical and molecular genetic study of 1,765 cases with long-term follow-up. Am J Surg Pathol 2005;29:52–68.CrossRefPubMedGoogle Scholar
  9. 9.
    Fujimoto Y, Nakanishi Y, Yoshimura K, Shimoda T. Clinicopathologic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors: analysis of results in 140 surgically resected patients. Gastric Cancer 2003;6:39–48.CrossRefPubMedGoogle Scholar
  10. 10.
    Goh BK, Tan YM, Chung YF, Cheow PC, Ong HS, Chan WH, Chow PK, Soo KC, Wong WK, Ooi LL. Critical appraisal of 232 consecutive distal pancreatectomies with emphasis on risk factors, outcome and management of the postoperative pancreatic fistula. A 21-year experience at a single institution. Arch Surg 2008;143:956–965.CrossRefPubMedGoogle Scholar
  11. 11.
    Kleef J, Diener MK, Z’graggen K et al. Distal pancreatectomy: risk factors for surgical failure in 302 consecutive cases. Ann Surg 2007;245:573–582.CrossRefGoogle Scholar
  12. 12.
    Fletcher CD, Berman JJ, Corless C et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002;33:459–465.CrossRefPubMedGoogle Scholar
  13. 13.
    Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo C, Izbicki J, Neoptolemos J, Sarr M, Traverso W, Buchler M. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery 2005;138:8–13.CrossRefPubMedGoogle Scholar
  14. 14.
    Shoup M, Brennan MF, McWhite K, Leung DH, Klimstra D, Conlon KC. The value of splenic preservation with distal pancreatectomy. Arch Surg 2002;137:164–168.CrossRefPubMedGoogle Scholar
  15. 15.
    Dematteo RP, Heinrich MC, El-Rifai WM et al. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 2002;33:466–477.CrossRefPubMedGoogle Scholar
  16. 16.
    Hsu KH, Yang TM, Shan YS, Lin PW. Tumor size is a major determinant of recurrence in patients with respectable gastrointestinal stromal tumor. Am J Surg 2007;194:148–152.CrossRefPubMedGoogle Scholar
  17. 17.
    Goh BK, Chow PK, Chuah KL, Yap WM, Wong WK. Pathologic, radiologic and PET scan response of gastrointestinal stromal tumors after neoadjuvant treatment with imatinib mesylate. Eur J Surg Oncol 2006;32:961–963.CrossRefPubMedGoogle Scholar
  18. 18.
    DeMatteo RP, Ballman KV, Antonescu C et al. Adjuvant imatinib mesylate after resection of localized primary gastrointestinal stromal tumour: a randomized, double-blind, placebo-controlled trial. Lancet 2009;373:1097–104.CrossRefPubMedGoogle Scholar
  19. 19.
    Miettinen M, Makhlouf H, Sobin LH et al. Gastrointestinal stromal tumors of the stomach. Review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006;130:1466–1478.PubMedGoogle Scholar

Copyright information

© The Society for Surgery of the Alimentary Tract 2010

Authors and Affiliations

  • Brian K. P. Goh
    • 1
  • Pierce K. H. Chow
    • 1
    • 2
  • Sittampalam M. Kesavan
    • 3
  • Wai-Ming Yap
    • 3
  • Yaw-Fui A. Chung
    • 1
  • Wai-Keong Wong
    • 1
  1. 1.Department of SurgerySingapore General HospitalSingaporeSingapore
  2. 2.Duke-NUS Graduate Medical SchoolSingaporeSingapore
  3. 3.Department of PathologySingapore General HospitalSingaporeSingapore

Personalised recommendations